Immunovia has received final approval to begin patient testing for the IMMray PanCan-d test – the first blood test on the market dedicated to the early detection of pancreatic cancer.
Approval was received from the Massachusetts Department of Public Health on 3 August. The test recognises biomarker signatures and has the potential to increase the survival of patients by detecting pancreatic cancer when surgical resection is still possible.
IMMray is a technology platform for developing bioinformatics-assisted, blood-based tests with the potential to detect complex diseases earlier and with higher accuracy. The first application of this technology is IMMray PanCan-d, which is a blood test designed for early detection of pancreatic cancer (PDAC stage I & II). The test is offered exclusively as a laboratory developed test (LDT) by Immunovia.
Immunovia’s test platform is based on advanced bioinformatics, used to single out a few relevant biomarkers to form a unique disease fingerprint for complex diseases such as pancreatic cancer, other cancers and autoimmune diseases.
